Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.59 |
| ▸ | APP | P05067 | 3/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 3/20 | 0.53 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206731 | 1.00 | MAOA (0.61) | MAOACHRM2APPSIGMAR1BCHE | |
| SCHEMBL7207674 | 0.98 | MAOA (0.58) | MAOACHRM2APPSIGMAR1BCHE | |
| SCHEMBL7202711 | 0.94 | SIGMAR1 (0.57) | MAOACHRM2APPSIGMAR1BCHE | |
| SCHEMBL2538898 | 0.87 | MEN1 (0.53) | MAOACHRM2APPSIGMAR1BCHE | |
| SCHEMBL6164283 | 0.85 | MAOA (0.60) | MAOACHRM2SIGMAR1TMEM97 | |
| SCHEMBL9185975 | 0.85 | SIGMAR1 (0.44) | MAOACHRM2APPSIGMAR1BCHE | |
| SCHEMBL9326853 | 0.83 | APP (0.56) | CHRM2APPBCHEACHEMAOB | |
| SCHEMBL7202283 | 0.82 | MAOA (0.56) | MAOACHRM2SIGMAR1TMEM97 | |
| SCHEMBL22873879 | 0.81 | APP (0.49) | APPSIGMAR1BCHEACHEMAOB | |
| SCHEMBL12126534 | 0.80 | KCNH2 (0.72) | CHRM2APPBCHEACHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229037-A1 | Novel cationic amphiphiles | MASSING ULRICH (DE) | 2003-12-11 | — | — | US | disclosed |
| EP-1261620-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | Roche Diagnostics Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001057064-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | ROCHE DIAGNOSTICS CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229037-A1 | Novel cationic amphiphiles | ABHD16A, APMAP, ABCB4 | MAOA 3723/4885CHRM2 4796/4885APP 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.